Florida Attorney General Files Lawsuit Against Major Insulin Manufacturers Over Pricing Scheme
Florida Attorney General James Uthmeier has filed a lawsuit against three major insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, alleging an unlawful pricing scheme for insulin.
Tampa St. Petersburg, FL, September 23, 2026 —
Florida Attorney General James Uthmeier announced on Tuesday that the state has filed a lawsuit against three leading insulin manufacturers: Eli Lilly and Company, Novo Nordisk, and Sanofi. The legal action alleges that these pharmaceutical companies engaged in an unlawful pricing scheme for insulin, a critical medication for individuals with diabetes.
The lawsuit, filed by Attorney General Uthmeier, seeks to address concerns over the rising cost of insulin, which has become a significant financial burden for many Floridians. While the specific details of the alleged unlawful pricing scheme were not fully elaborated upon in the initial announcement, the core accusation centers on the manufacturers’ practices related to the price of insulin.
The complaint was formally lodged against Eli Lilly, Novo Nordisk, and Sanofi, companies that together dominate a substantial portion of the global and U.S. insulin market. These manufacturers have been a focal point of public scrutiny and legislative debate regarding drug pricing in recent years. The rising cost of insulin has prompted widespread calls for greater affordability and accessibility, particularly for the millions of Americans living with diabetes who rely on it for survival.
Attorney General Uthmeier’s office stated that the lawsuit aims to hold the companies accountable for practices that may have artificially inflated prices and harmed consumers. The legal proceedings are expected to delve into the manufacturers’ pricing strategies, including any potential collusion or anti-competitive behaviors.
The specific amounts of financial damages, the timeline of the alleged scheme, or the exact nature of the pricing practices are details that the lawsuit intends to explore through discovery. No court dates or further procedural steps were immediately provided following the announcement of the filing. The manufacturers have not yet issued a public statement in response to the lawsuit. This action by Florida’s Attorney General adds to a growing number of state and federal efforts aimed at curbing prescription drug costs, with a particular focus on essential medications like insulin.
Story summarized from the original created by Ashley Suter on www.wfla.com, see more information here.
Media gallery
